Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst sentiment is moderately bullish: Fifteen firms rate Dyne Therapeutics a consensus “Moderate Buy,” with 10 buys and two strong buys. The average 12-month price target is $34.42 versus the stock’s $26.10 opening price.
• Shares have gained but the company missed earnings expectations: DYN recently traded near its one-year high of $27.31, while reporting a quarterly loss of $1.08 per share—worse than the $0.75 loss analysts expected.
• Insider selling has been significant: Insiders sold about $99.45 million of stock over the past three months, including a director’s $54 million sale, while institutional investors own approximately 96.68% of the company.

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, ten have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $34.4167.

Several equities analysts have recently issued reports on the stock. Morgan Stanley cut their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Wall Street Zen cut shares of Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a "buy" rating on the stock. Cantor Fitzgerald initiated coverage on shares of Dyne Therapeutics in a research note on Thursday, July 23rd. They set an "overweight" rating on the stock. Finally, Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 15th.

Dyne Therapeutics Stock Up 0.5%

Shares of DYN stock opened at $26.10 on Friday. The stock's fifty day moving average price is $23.68 and its 200 day moving average price is $19.78. Dyne Therapeutics has a 1-year low of $11.92 and a 1-year high of $27.31. The company has a market cap of $4.87 billion, a price-to-earnings ratio of -7.84 and a beta of 1.07. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, research analysts expect that Dyne Therapeutics will post -3.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Jason P. Rhodes sold 2,160,516 shares of Dyne Therapeutics stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company's stock, valued at $10,723,650. The trade was a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Erick Lucera sold 2,362 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have bought 6,500 shares of company stock worth $114,000 and have sold 4,139,196 shares worth $99,449,852. 9.46% of the stock is owned by insiders.

Institutional Trading of Dyne Therapeutics

Several large investors have recently made changes to their positions in DYN. T. Rowe Price Investment Management Inc. increased its stake in shares of Dyne Therapeutics by 523.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after acquiring an additional 14,727,667 shares during the period. BlackRock Inc. acquired a new position in Dyne Therapeutics during the second quarter valued at $275,500,000. Jupiter Topco LLC acquired a new position in Dyne Therapeutics during the second quarter valued at $266,634,000. Orbis Allan Gray Ltd acquired a new position in Dyne Therapeutics during the fourth quarter valued at $93,926,000. Finally, Adage Capital Partners GP L.L.C. purchased a new stake in Dyne Therapeutics in the second quarter valued at $30,378,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source